ICA-EASL JOINT MEETING – Vienna (Austria) April 22nd, 2015

ICA-EASL JOINT MEETING

Vienna  (Austria) April 22nd, 2015 at 8.00 a.m.

BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS

Chairs; M. Bernardi, P. Angeli

Introduction

8.00-8.10

M. Bernardi (Bologna, Italy)

Microbiology of bacterial infections in cirrhosis; how has it changed over the last years?

PL Viale (Bologna, Italy)

8.10-8.30

The microbiome and bacterial translocation in cirrhosis

B. Schnabl (San Diego, CA, US)

8.30-8.50

Non antibiotic prophylaxis of bacterial infections in cirrhosis; where we are and where  we are going to?

G. Garcia-Tsao  (New Haven, US)

8.50-9.10

Discussion 9.10-9.30

Coffee break 9.30-10.00

New protocols of empirical antibiotic treatment of bacterial infections in cirrhosis

J- Fernandez (Barcelona, Spain)

10.00-10.20

The changing role of albumin in the management of patients with cirrhosis and bacterial infections: from plasma expander to immuneregulator and anti-inflammatory agent

R. Mookerjee, (London, U.K)

10.20-10.40

Discussion 10.40-10.50

Conclusions 10.50-11.00

P. Angeli (Padova, Italy)

ICA-APASL JOINT MEETING – Istanbul (Turkey) March, 13th 2015

Dear Collegues

We have the pleasure to announce two other events that will be supported by the International Club of Ascites (ICA).

ICA-APASL JOINT MEETING

Istanbul (Turkey) March, 13th 2015 at 1.30 p.m.

Safety of non-selective beta-blockers (NSBB) and proton pump inhibitors (PPI) in advanced cirrhosis and ascites

A 1 hours and 30 min meeting, starting 1.30 pm

Chairmen: Paolo Angeli & Shiv Sarin

Introduction and welcome Paolo Angeli
New concept on the use of NSBB in cirrhosis: ”The window hypothesis” 18+2 Aleksander Krag -
Safety of NSBB in refractory ascites 18+2 Thomas Sersté
Safety of NSBB and PPI: Relations to SBP and AKI, 18+2 Mathias Mandorfer
NSBB and PPI in advanced cirrhosis: Recommendations for clinical practice 18+2 Asian speaker – suggestion from Shiv
Discussion

Wrap up

10 Shiv Sarin

ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL) 23RD CONFERENCE

ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL) 23RD CONFERENCE

BRISBANE (AUSTRALIA) 12-15 MARCH 2014

 

FRIDAY 14TH AFTEROON SESSION

 

NEW insights ON THE USE OF ALBUMIN IN CIRRHOSIS WITH ASCITES (concurrent 6 : h 16.00-17.40)

Chairmen: ProF. S. Sarin, Prof. P. Angeli

  • Arun Sanyal The development of the use of use of albumin in cirrhosis with ascites
  • Paolo Angeli Biological effects of albumin: new evidences
  • Shiv Sarin Alterations of albumin molecule in cirrhosis and ACLF
  • Florence Wong Relevance of albumin correction for hypoalbuminemia: a rational approach

 

  • Discussion

ICA-EASL Joint Meeting, 24th April 2013, Amsterdam (Netherlands)

THE USE OF ALBUMIN IN CIRRHOSIS WITH ASCITES: A RISK OF SPREAD BETWEEN GUIDELINES AND CLINICAL PRACTICE?
Chairmen: Prof. M. Bernardi (EASL), Prof. P. Angeli (ICA)

Introduction
8.00-8.15 (V. Arroyo) The development of the use of use of albumin in cirrhosis with ascites

New insights on albumin in cirrhosis with ascites

a) 8.15-8.30 (P. Angeli) Biological effects of albumin: new evidences
b) 8.30-8.45 (P. Caraceni) The relevance of the alterations of albumin molecule
c) 8.45-9.00 (M.Otagiri) Development of recombinant serum albumin
 

9.00-9.15 (M. Bernardi) The use of albumin in a health care systems with limited resourses

Discussion (9.15-9.30)

Break (hr 9.30-10.00)

Potential strategies to limit the use of albumin in cirrhosis with ascites

a) 10.00-10.15 (C. Alessandria) Potential strategies to limit the use of albumin in therapeutic paracentesis
b) 10.15-10.30 (A. Gadano) Can we try to rationalize the use of albumin in patients with SBP?
c) 10.30-10.45 (P. Kamath) Can we try to rationalize the use of albumin in HRS?

Discussion (10.45-11.00)
 
Proposed Faculty
Paolo Angeli, M.D. Department of Clinical and Experimental Medicine, University of Padova, Italy,

Mauro Bernardi, M.D. Department of Clinical Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy,
mauro.

Pere Gines Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain, .es

P. Caraceni  Department of Clinical Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy,
paolo.
M. Otagiri Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
-u.ac.jp.
Carlo Alessandria Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital – University of Turin, Turin, Italy.

Adrian Gadano Sección Hepatología, Hospital Italiano, Buenos Aires, Argentina.
adrian..ar
gadano.

Patrick Kamath Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. kamath.

Workshop on “The Management of Renal Dysfunction in Patients with Cirrhosis” (13th-15th December 2012, Padova-Venice, Italy)

INTERNATIONAL CLUB OF ASCITES
Current address: Dept. of Medicine, University of Padova, via Giustiniani 2, cap 35128 Padova (Italy)
Phone n°: +390498212004 ; Fax n°: +390498218676 ; Web site : http://www.icascites.org/
Workshop on
“The Management of Renal Dysfunction in Patients with Cirrhosis”
(13th-15th December 2012, Padova-Venice, Italy)
Padova 14th December 2012 (8.30 – 17.00)
Welcome and introduction
P. Angeli (Padova, Italy)
Chair: V. Arroyo (Barcelona, Spain), M. Bernardi (Bologna, Italy)
8.30-11.00 1st Session: Round Table on clinical relevance of an increase in serum creatinine to a final value below 1.5 mg/dl in patients with cirrhosis: comparison among new available data
- M. Guevara (Barcelona, Spain)
- S. Piano (Padova, Italy)
- G. Garcia-Tsao (New Haven, CT, USA)
- F. Wong (Toronto, Canada)
- S.  Sarin (New Dehli, India)
Chair: R. Moreau (Paris, France), F. Wong (Toronto, Canada)
11.00-13.30 2nd Session: What about the new tools for the differential diagnosis among the different phenotypes of acute renal failure in patients with cirrhosis?
- Subclinical acute tubular necrosis in patients with cirrhosis (R. Kim, Rochester, MN, USA)
- The potential role of human neutrophil gelatinase-associated lipocalin (NGAL) (P. Gines, Barcelona, Spain)
- The potential role of cistatin C (A. Gerbes, Munich, Germany)
- The role of renal biopsy in patients with cirrhosis: (R. Moreau, Paris, France)
13.30-14.30 Lunch
14.30-17.00 3rd Session: New insights in the pathophysiology of HRS
Chair: G. Thiene (Padova, Italy)
“Giovanni Battista Morgagni” State of the art lecture: Peripheral arterial vasodilation: new molecular mechanisms (R. W. Schrier, Denver, CO, USA)
Chair: P. Gines (Barcelona, Spain), A. Gatta (Padova, Italy)
- The role of the impairment of cardiac output (V. Arroyo, Barcelona, Spain)
- Reduced cardiac contractility: molecular mechanisms (S. Lee, Calgary, Canada)
- Beside renal hypoperfusion: the role of inflammation (R. Mookerjee, London, U.K)
____________________________________________________________________
Venice 15th December 2012 (8.30 – 13.30)
Chair: G. Garcia-Tsao (New Haven, CT, USA), R. W. Schrier (Denver, CO, USA)
8.30-11.00 4th Session: How can we better finalize the diagnosis of HRS?
- When should be started the plasma volume expansion? (F. Salerno, Milano, Italy)
- How to monitor the plasma volume expansion? (P. Caraceni, Bologna, Italy)
- What about the 2.5 mg/dl cut-off for the diagnosis of type 1 HRS? (T.D. Boyer, Tucson, AZ, USA)
- What about the diagnosis of HRS in patients with chronic kidney disease? (K. Moore, London, UK)
Chair: T.D. Boyer (Tucson, AZ, USA), G. Laffi (Firenze, Italy)
11.00-13.30 5th Session: How can we better finalize the treatment of HRS?
- When type 2 HRS should be treated with terlipressin and albumin? (M. Bernardi, Bologna, Italy)
- How to monitor the treatment with terlipressin and albumin? (P. Gines, Barcelona, Spain)
- How to manage priority allocation to liver transplantation in responders? (P. Angeli, Padova, Italy)
- How to manage the non response? (F. Durand, Paris, France)
Conclusive remarks
A. Gatta (Padova, Italy), V. Arroyo (Barcelona, Spain)
13.30-14.30 Lunch
Scientific Committee of the International Club of Ascites
· Carlo Alessandria (Torino, Italy)
· Paolo Angeli (Padova, Italy)
· Adrian Gadano (Buenos Aires, Argentina)
· Ray Kim (Rochester, MN, USA)
· Alexander Krag (Copenaghen, Demnark)
· Arun Sanyal (Richmond, VA, USA)
· Shiv Sarin (New Dehli, India)
Faculty
· Paolo Angeli (Padova, Italy)
· Vicente Arroyo (Barcelona, Spain)
· Mauro Bernardi (Bologna, Italy)
· Thomas D. Boyer (Tucson, AZ, USA)
· Paolo Caraceni (Bologna, Italy)
· Francois Durand (Paris, France)
· Gudalupe Garcia-Tsao (New Haven, CT, USA)
· Angelo Gatta (Padova, Italy)
· Alexander Gerbes (Munich, Germany)
· Pere Gines (Barcelona, Spain)
· Monica Guevara (Barcelona, Spain)
· Ray Kim (Rochester, MN, USA)
· Giacomo Laffi (Firenze, Italy)
· Sam Lee (Calgary, Canada)
· Raj Mookerjee (London, UK)
· Kevin Moore (London, UK)
· Richard Moreau (Paris, France)
· Salvatore Piano (Padova, Italy)
· Francesco Salerno (Milano, Italy)
· Shiv Sarin (New Delhi, India)
· Robert W. Schrier (Denver, CO, USA)
· Gaetano Thiene (Padova, Italy)
· Florence Wong (Toronto, Canada)
International Club of Ascites Workshop venue:
- on 14th December: Aula Morgagni, Policlinico Universitario, Via Giustiniani 2, Padova (Italy)
- on 15 th December: Giustiniani Palace Hotel, Venice (Italy) Santa Croce, San Stae, 2070, Venice (Italy)
The event will take place under the auspices of:
- Regione Veneto (Italy)
- University of Padova (Italy)
- Italian Association for the Study of Liver Disease (AISF)
- Foundation “Lionello Forin Hepatos
Sponsorships for the International Club of Ascites Workshop:
- Ikaria USA (major sponsor)
- Grifols Europe
- Kedrion Italy
- Novartis Italy

APALS-ICA JOINT MEETING, TAIPEI, 17th February 2012 (15.30-17.30)

APALS-ICA JOINT MEETING, TAIPEI, 17th February 2012 (15.30-17.30)

Bacterial infections in patients with cirrhosis
Chairs:  Prof Po-Ren Hsueh, Prof. Garcia-Tsao
• Welcome and introduction

• The new epidemiology of nosocomial bacterial infections in patients with cirrhosis: therapeutical implications (Javier Fernandez 20 min.)

• Bacterial translocation in cirrhosis: pathophysiology and clinical implications (20 min. Joseph Such)

• Bacterial infections: from bench to bedside (Ming-Hung Tsai, 20 min.) 

• Sepsis in patients with acute on chronic liver failure: new strategies for prevention and treatment (Shiv Sarin, 20 min)

• Pathophysiological basis of the use of albumin in the prevention of haemodynamic derangement due to bacterial infections in patients with cirrhosis (Paolo Angeli 20 min.)

• Discussion 20 min

EASL-IAC Joint Workshop: RENAL DYSFUNCTION IN CIRRHOSIS IN THE ERA OF AKI: TOWARDS A NEW DEFINITION WEDNESDAY, MARCH 30, 2011

WEDNESDAY, MARCH 30, 2011

09:00-12:00 EASL-IAC (International Club of Ascites) Joint Workshop: RENAL DYSFUNCTION IN

CIRRHOSIS IN THE ERA OF AKI: TOWARDS A NEW DEFINITION Chairs: M. Bernardi, Italy P.

Angeli. Italy

09:00 Introduction: Renal dysfunction in patients with cirrhosis: the long way traveled so

far by hepatologists V. Arroyo, Spain Critical points in the actual definitions of renal

dysfunction in cirrhosis

09:15 The definition of renal dysfunction in cirrhosis in the era of AKI ; is a 0.3 mg/dl

change enough in the setting of cirrhosis for diagnosis of AKI? M. Nadim, USA

09:30 The actual “grey zones” about the classification of patients with cirrhosis and

renal dysfunction. F. Wong, Canada

09:45 How to improve the differential diagnosis among HRS and ATN? C. Parihk, USA

10:00 Discussion S. Møller, Denmark C.L. Davis, USA Critical points in the treatment of

renal dysfunction in cirrhosis

10:15 How to optimize the pharmacological treatment for type 1 HRS A.J. Sanyal, USA

10:30 Coffee Break

11:00 What after the failure of vasoconstrictors and albumin in order to be effective and

to avoid futility? Extracorporeal renal and/or hepatic support, TIPS F. Salerno, Italy

11:15 Combined liver and kidney transplantation (CLKT): when is it indicated in patients

with cirrhosis and renal dysfunction? C.L. Davis, USA

11:30 Discussion M. Guevara, Spain M. Nadim, USA

11:45 Conclusions: Proposal of a new classification of renal dysfunction in patients with

cirrhosis: towards a consensus based on a multidisciplinary approach ? P. Ginès, Spain

IAC_Ascites_UPDATED PROGRAMME

APASL – IAC Joint meeting, Saturday, February 19, 2011

Saturday, February 19, 2011
APASL – IAC Joint meeting:
Topic: Hyponatremia: pathophysiology and
Management (08:00-09:30 a.m.)

1. Fluid-electrolyte disturbances in cirrhosis - Arun Sanyal, USA
2. Mechanisms and pathophysiology of hyponatremia in cirrhosis - Lupe Garcia, USA
3. Relevance of hyponatremia in acute and chronic liver failure – Paolo
Angeli, Italy           
4. Treatment of hyponatremia  -  S K Sarin (India)
5. Workshop – Presentation of a hyponatremia case

IAC-AASLD JOINT RESEARCH WORKSHOP, October 31, 2010

IAC-AASLD JOINT RESEARCH WORKSHOP

BIOMARKER DISCOVERY FOR RENAL DYSFUNCTION IN CIRRHOSIS

Sunday 31 October, 2010 (6.15-8.15 p.m.)

(Hotel Sheraton, Commowealth Room, Boston 2010)
Directors: Arun Sanyal M.D. and Paolo Angeli M.D.

Session 1 (hr. 6.15 p.m.-7.15 p.m.)

Chairmen: Vicente Arroyo M.D. , Florence Wong, M.D.

- Acute Kidney Injury Definitions: are they valid for early detection of renal dysfunction in patients with cirrhosis?(20 min) (Mitra Nadim, M.D.)
- Novel biomarkers of acute kidney injury in cirrhosis and their application in patients with cirrhosis (20 min) (Chirag Parikh, M.D.)

Discussion (20 min)
 
Session 2 (7.15 p.m. -8.15 p.m.)

Chairmen: Guadalupe Garcia-Tsao M.D. and Sam Lee M.D.

- Renal response to systemic infection: implications for biomarker development (20 min) (Richard Moreau, M.D.)
- Renal response to hypoperfusion: implications for biomarker development (20 min) (Rajiv Jalan M.D. )

Discussion  (20 min)


Proposed Faculty

Paolo Angeli M.D.
Vicente Arroyo M.D. ,
Florence Wong, M.D.
Guadalupe Garcia-Tsao, M.D.
Rajiv Jalan, M.D.
Sam Lee, M.D.
Richard Moreau, M.D.
Mitra Nadim, M.D.
Chirag Parikh, M.D.
Arun Sanyal

IAC-AASLD Joint Meeting in 2010


RATIONALE AND AIMS OF THE AASLD-IAC JOINT MEETING
BIOMARKER DISCOVERY FOR RENAL DYSFUNCTION IN CIRRHOSIS
Renal complications are common in cirrhosis, especially in patients with refractory ascites, and they can negatively impact the patients’ survival. The International Ascites Club has set out clear diagnostic criteria for both acute and chronic forms of HRS. Nevertheless, IAC has not delineated guidelines for the diagnosis of other forms of renal impairment in cirrhosis, be they acute or chronic. Well-accepted definitions and staging systems for chronic kidney disease (CKD) and acute kidney disease (AKI) exist but they have been not applied up to now in patients with chronic liver disease. In addition either IAC criteria as well as the more recent definitions of CKD and AKI are based on serum creatinine. Serum creatinine is notoriously inaccurate in the diagnosis of renal dysfunction in cirrhosis. Patients with cirrhosis often have low serum creatinine levels, due to reduced production of creatinine from creatine in the liver and significant muscle wasting. Thus, serum creatinine in patients with cirrhosis can still be within the normal range despite significant renal dysfunction. The use of creatinine clearance in cirrhosis to assess renal function is also unreliable because of the falsely low serum creatinine in these patients, coupled with a relatively increased renal tubular creatinine secretion compared to filtered creatinine. Formulae such as the Cockcroft–Gault and Modification of Diet in Renal Disease (MDRD), which are based on the serum creatinine concentrations, will also overestimate the GFR in patients with cirrhosis. Thus, other biological markers should be introduced and validated in patients with advanced liver disease. Working together, nephrologists, hepatologists, intensivists can discover and propose novel biomarkers taking into account the complexity of the pathophysiology of renal dysfunction in patients with chronic liver disease. Although there is considerable evidence that renal failure in patients with cirrhosis is primarily related to disturbances in circulatory function, several other factors can be involved such as etiologic factors underlying the liver disease, bacterial infections, cholestasis, NSAIDs or other drugs, co-morbidities. As a consequence the spectrum of renal histopathological changes in cirrhosis is extensive and individuals may have coincident glomerular and tubulointerstitial, acute and chronic lesions. The mulitidisciplinary approach to renal dysfunction in cirrhosis, on which the workshop is focused, let it possible to discuss in depth this topic. The proposed speakers, either hepatologists or nephrologists, are well known experts of renal dysfunction in cirrhosis.

Paolo Angeli, M.D.

Rationale of the MEETING-IAC-AASLD

APASL-IAC Joint symposium, March 26, 2010

APASL-IAC JOINT SYMPOSIUM, 26 MARCH 2010 (session time 2-4 p.m.), CHINA NATIONAL CONVENTION CENTER, BEIJING, CHINA RENAL DYSFUNCTION IN CIRRHOSIS (Chairperson: Samuel S. Lee, Calgary, Canada)
Sponateneous Bacterial Peritonitis, New IAC Guidelines (Ruben Terg, Buenos Aires, Argentina) Acute Kidney Injury in Liver Diseases (Shiv. K. Sarin, New Dehli, India) Renal Perfusion and Approach to Prevention of Renal Injury (Arun J. Sanyal, Richmond, US) Role of Renal Support and Intervention Devices in Renal Dysfunction of Cirrhosis (Paolo Angeli, Padova, Italy) Pathogenesis and Management of Hyponatremia in Advanced Cirrhosis (W. Ray. Kim, Rochester, US).